The European Centre for Disease Prevention and Control released a report outlining the current situation and detailing options for response to mcr-1’s growing presence. The organization recommends labs adopt improved methods for detecting bacterial resistance to last-resort drug treatments; improving global, national and local surveillance of bacteria carrying the resistance gene to identify and monitor the spread of resistance; and more timely clinical management of treating resistant infections. This includes testing microbiological samples for their colistin susceptibility before administering the drug.
The report also outlines antimicrobial stewardship program must-haves for hospitals, as well as infection control precautions related to device reprocessing and hygiene, among other factors, that play a role in controlling the spread of superbugs.
Read the full report here.
More articles on antibiotic resistance:
Many possible STD patients get unnecessary antibiotics, study finds
Americans underestimate threat of antibiotic resistance: 3 survey findings
Why are physicians more likely to prescribe antibiotics later in the day? 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.